Difinsa53
Radiodermatitis
ProTechSure Scientific, Inc.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Radiodermatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
BETAMETHASONE Cairo University | Phase 4 | BB |
Olea europaea oil Cairo University | Phase 4 | BB |
Urea University of Brasilia | Phase 3 | BB |
Mometasone North Central Cancer Treatment Group | Phase 3 | BB |
Chamomilla recutita University of Brasilia | Phase 3 | BB |
View all 33 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →